How to Inject Wegovy in Your Stomach: A Comprehensive Guide

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The abdomen is one of three subcutaneous injection sites the Wegovy label permits — it lists the abdomen, thigh, or upper arm — but this article deliberately will not walk you through the steps, and the reason comes straight from the label itself. The Wegovy prescribing information instructs healthcare providers to inform patients which Wegovy presentation they will receive and to ensure they receive training appropriate for that specific presentation, and states that if the presentation changes, the patient must be retrained. Technique is device-specific and legally belongs to the Instructions for Use in your carton plus the person who prescribed it. What a general-audience article can do is explain what the label says about site, timing and safety — and clear up the most common misconception about the abdomen in particular.

Why There Is No One Set of Steps

Wegovy is not a single device. Its Dosage Forms and Strengths section lists single-dose pens at 0.25, 0.5, 1, 1.7, 2.4 and 7.2 mg (the last being Wegovy HD); single-dose syringes at 0.25 through 2.4 mg; and a single-patient-use Wegovy FlexTouch pen containing 9.6 mg/3 mL that delivers four 2.4 mg doses. Each of those has its own Instructions for Use, and the label carries a separate IFU for the pen, for Wegovy HD, and for other presentations.

The label makes the consequence explicit: after training, a patient may self-inject only if the healthcare provider determines it can be properly administered, and Wegovy FlexTouch specifically is not recommended for self-administration by people who are visually impaired. An article that gave you generic steps would, for some readers, be describing the wrong device.

What the Label Says About Where to Inject

The Wegovy label directs subcutaneous injection in the abdomen, thigh, or upper arm, and states that the injection site can be changed without any dosage modification. It also directs rotating injection sites with each dose. Ozempic's label carries the same three-site language for semaglutide injection in type 2 diabetes.

So the abdomen is a valid site, not a required one. If someone has been told the stomach is the only correct place, that is not what the labeling says — and the reason people believe it is usually a misunderstanding about absorption.

The Absorption Myth, Settled by the Label

The most persistent claim about abdominal injection is that it absorbs better or works faster. The clinical pharmacology section of the semaglutide labeling addresses this directly: similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm. Absolute bioavailability of semaglutide is 89%, maximum concentration is reached 1 to 3 days after a dose, and the elimination half-life is approximately one week — long enough that semaglutide remains in circulation for about five to seven weeks after a final dose.

That pharmacokinetic profile is why site choice does not meaningfully change results. A once-weekly drug with a week-long half-life reaches steady state over weeks, not hours. Small differences in local tissue at any one site are smoothed out entirely. Choose based on what your provider recommends and what you can reach comfortably, not on a theory about faster uptake.

Timing: What the Label Permits

Wegovy injection is administered once weekly, on the same day each week, at any time of day, with or without meals. The label states that the time of day and the injection site can both be changed without a dosage modification. There is no meal-timing requirement and no time-of-day requirement for the injectable — those constraints belong to the oral semaglutide tablets, which are a different formulation with different absorption.

Questions about changing your day of the week, what to do about a disrupted schedule, or how a planned procedure affects your timing are all things the label routes to your prescriber and your pharmacy label. The Wegovy label, for example, instructs patients to inform their healthcare providers before any planned surgery or procedure, because of the pulmonary aspiration warning added to Warnings and Precautions.

Injection Site Reactions Are Uncommon

The label quantifies this. In clinical trials in adults for weight reduction, injection site reactions — including pruritus, erythema, inflammation, induration and irritation — occurred in 1.4% of Wegovy-treated patients versus 1% of patients receiving placebo. That is a small absolute difference, and it is one reason site rotation is directed rather than treated as a major clinical concern.

The more common adverse reactions with semaglutide are gastrointestinal. Nausea, vomiting and diarrhea were the most frequent reasons for permanently discontinuing Wegovy in the adult trials. Those are systemic effects of the drug, not consequences of where the needle went, so changing sites is not a strategy for managing them.

Never Share a Pen — Even With a New Needle

Semaglutide labeling carries an explicit Warnings and Precautions subsection on pen sharing. The Wegovy label states that Wegovy FlexTouch must never be shared between patients even if the needle is changed, because pen-sharing poses a risk for transmission of blood-borne pathogens. Ozempic's label carries the equivalent warning for its pens.

This is not a hygiene suggestion. It is a labeled safety warning about bloodborne pathogen transmission, and it applies regardless of how carefully a needle is swapped or how well someone knows the person they would be sharing with.

Compounded Semaglutide Is Not Wegovy

If your prescription is for compounded semaglutide rather than Wegovy, the distinction matters here specifically. Compounded preparations are not FDA-approved finished products; the FDA does not review them for safety, effectiveness or quality before marketing, and they do not ship with the FDA-approved Instructions for Use that accompanies a brand pen. Concentration, container and device can all differ.

That makes the pharmacy that dispensed it and the prescriber who wrote it your only reliable source for handling questions. PlexusDx dispenses through licensed 503A compounding pharmacies, and every protocol includes clinician access precisely because these questions should be answered by someone looking at your specific prescription rather than a search result.

Frequently Asked Questions

Can Wegovy be injected in the stomach?

Yes. The Wegovy label lists the abdomen as one of three permitted subcutaneous injection sites, alongside the thigh and the upper arm, and states that the site can be changed without any dosage modification. It also directs rotating sites with each dose. The specific technique for your device comes from the Instructions for Use packaged with your product and the training your prescriber provides.

Does injecting in the abdomen work better than the thigh or arm?

No. The clinical pharmacology section of semaglutide labeling states that similar exposure was achieved with subcutaneous administration in the abdomen, thigh, or upper arm. Absolute bioavailability is 89% and the elimination half-life is about one week, so a once-weekly drug reaching steady state over weeks is not measurably affected by which of the three approved sites you use.

Why will you not give me step-by-step injection instructions?

Because Wegovy ships in several presentations — single-dose pens at six strengths, single-dose syringes, and a multi-dose FlexTouch pen — each with its own FDA-approved Instructions for Use. The label directs providers to train patients for their specific presentation and to retrain them if it changes. Generic steps would be wrong for some readers, which is why this belongs with your prescriber and pharmacist.

Are injection site reactions common with semaglutide?

They are relatively uncommon. In adult weight-reduction clinical trials, injection site reactions including itching, redness, inflammation, induration and irritation occurred in 1.4% of Wegovy-treated patients compared with 1% of placebo-treated patients. Gastrointestinal effects such as nausea, vomiting and diarrhea were far more frequent and were the leading reasons for discontinuation in those trials.

Can I share a pen with my spouse if we change the needle?

No. Semaglutide labeling includes a dedicated warning stating that a pen must never be shared between patients even if the needle is changed, because pen-sharing poses a risk for transmission of blood-borne pathogens. This applies to Wegovy FlexTouch and to Ozempic pens alike, and it holds regardless of the relationship between the people involved or how the needle is handled.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.